2023
Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Jajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, PMCID: PMC10541552, DOI: 10.1182/blood.2022018591.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesErythroblastosis, FetalErythrocytesFemaleHumansImmune ToleranceImmunosuppression TherapyInfant, NewbornIsoantibodiesIsoantigensRho(D) Immune GlobulinConceptsAntibody-mediated immunosuppressionRBC alloantigensImmune responseFetal red blood cell antigensTarget antigenRed blood cell antigensRh immune globulinMaternal immune responseBlood cell antigensInclusion of antibodiesRBC removalAnti-RhD antibodiesAbility of antibodiesImmune globulinAntibody responseHemolytic diseaseRBC clearanceCell antigensFetal RBCsAntibody characteristicsAlloantigensSimilar interventionsAntibodiesAntigenPolyclonal antibody preparation18 years of face transplantation: Adverse outcomes and challenges
Longo B, Pomahac B, Giacalone M, Cardillo M, Cervelli V. 18 years of face transplantation: Adverse outcomes and challenges. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 87: 187-199. PMID: 37879143, DOI: 10.1016/j.bjps.2023.09.043.Peer-Reviewed Original ResearchConceptsAllograft lossAdverse outcomesFace transplantationMedian timeStandard of careGoogle Scholar databasesFace transplant teamHeterogeneity of casesAllograft removalChronic rejectionInfectious complicationsIrreversible rejectionMajor complicationsTransplant centersTransplant casesTransplant teamPatient deathPRISMA guidelinesComplicationsSystematic reviewTransplantationScholar databasesSingle center approachSignificant riskPeer-reviewed literatureCalcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment optionsCellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionHumansImmune ToleranceImmunosuppression TherapyTransplantation, HomologousVascularized Composite AllotransplantationConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesCrusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.
Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCellulitisDermatitis, ExfoliativeGranulomatosis with PolyangiitisHumansIatrogenic DiseaseImmunosuppression TherapySarcoptes scabieiScabiesConceptsCrusted scabiesMedication-induced immunosuppressionTreatment of granulomatosisBone marrow transplantationDiagnosis of scabiesVar hominisIatrogenic immunosuppressionBroad differentialMarrow transplantationAutoimmune diseasesSolid organsRare caseSevere formPatientsImmunosuppressionErythrodermaScabiesInfectionEctoparasitic infectionsPolyangiitisGranulomatosisTreatmentMyelosuppressionTransplantationDiseaseInterplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu C, Alimohamed S, Bashir B, Berg S, Bilen M, Bowles D, Castellano C, Desai A, Elkrief A, Eton O, Fecher L, Flora D, Galsky M, Gatti-Mays M, Gesenhues A, Glover M, Gopalakrishnan D, Gupta S, Halfdanarson T, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson D, Joshi M, Khan H, Khan S, Knox N, Koshkin V, Kulkarni A, Kwon D, Matar S, McKay R, Mishra S, Moria F, Nizam A, Nock N, Nonato T, Panasci J, Pomerantz L, Portuguese A, Provenzano D, Puc M, Rao Y, Rhodes T, Riely G, Ripp J, Rivera A, Ruiz-Garcia E, Schmidt A, Schoenfeld A, Schwartz G, Shah S, Shaya J, Subbiah S, Tachiki L, Tucker M, Valdez-Reyes M, Weissmann L, Wotman M, Wulff-Burchfield E, Xie Z, Yang Y, Thompson M, Shah D, Warner J, Shyr Y, Choueiri T, Wise-Draper T, Fromowitz A, Gandhi R, Gartrell B, Goel S, Halmos B, Makower D, O' Sullivan D, Ohri N, Portes M, Shapiro L, Shastri A, Sica R, Verma A, Butt O, Campian J, Fiala M, Henderson J, Monahan R, Stockerl-Goldstein K, Zhou A, Bitran J, Hallmeyer S, Mundt D, Pandravada S, Papaioannou P, Patel M, Streckfuss M, Tadesse E, Gatson N, Kundranda M, Lammers P, Loree J, Yu I, Bindal P, Lam B, Peters M, Piper-Vallillo A, Egan P, Farmakiotis D, Arvanitis P, Klein E, Olszewski A, Vieira K, Angevine A, Bar M, Del Prete S, Fiebach M, Gulati A, Hatton E, Houston K, Rose S, Steve Lo K, Stratton J, Weinstein P, Garcia J, Routy B, Hoyo-Ulloa I, Dawsey S, Lemmon C, Pennell N, Sharifi N, Painter C, Granada C, Hoppenot C, Li A, Bitterman D, Connors J, Demetri G, Florez (Duma) N, Freeman D, Giordano A, Morgans A, Nohria A, Saliby R, Tolaney S, Van Allen E, Xu W, Zon R, Halabi S, Zhang T, Dzimitrowicz H, Leighton J, Graber J, Grivas P, Hawley J, Loggers E, Lyman G, Lynch R, Nakasone E, Schweizer M, Vinayak S, Wagner M, Yeh A, Dansoa Y, Makary M, Manikowski J, Vadakara J, Yossef K, Beckerman J, Goyal S, Messing I, Rosenstein L, Steffes D, Alsamarai S, Clement J, Cosin J, Daher A, Dailey M, Elias R, Fein J, Hosmer W, Jayaraj A, Mather J, Menendez A, Nadkarni R, Serrano O, Yu P, Balanchivadze N, Gadgeel S, Accordino M, Bhutani D, Bodin B, Hershman D, Masson C, Alexander M, Mushtaq S, Reuben D, Bernicker E, Deeken J, Jeffords K, Shafer D, Cárdenas A, Cuervo Campos R, De-la-Rosa-Martinez D, Ramirez A, Vilar-Compte D, Gill D, Lewis M, Low C, Jones M, Mansoor A, Mashru S, Werner M, Cohen A, McWeeney S, Nemecek E, Williamson S, Peters S, Smith S, Lewis G, Zaren H, Akhtari M, Castillo D, Cortez K, Lau E, Nagaraj G, Park K, Reeves M, O'Connor T, Altman J, Gurley M, Mulcahy M, Wehbe F, Durbin E, Nelson H, Ramesh V, Sachs Z, Wilson G, Bardia A, Boland G, Gainor J, Peppercorn J, Reynolds K, Rosovsky R, Zubiri L, Bekaii-Saab T, Joyner M, Riaz I, Senefeld J, Shah S, Ayre S, Bonnen M, Mahadevan D, McKeown C, Mesa R, Ramirez A, Salazar M, Shah P, Wang C, Bouganim N, Papenburg J, Sabbah A, Tagalakis V, Vinh D, Nanchal R, Singh H, Bahadur N, Bao T, Belenkaya R, Nambiar P, O’Cearbhaill R, Papadopoulos E, Philip J, Robson M, Rosenberg J, Wilkins C, Tamimi R, Cerrone K, Dill J, Faller B, Alomar M, Chandrasekhar S, Hume E, Islam J, Ajmera A, Brouha S, Cabal A, Choi S, Hsiao A, Jiang J, Kligerman S, Park J, Razavi P, Reid E, Bhatt P, Mariano M, Thomson C, Glace M, Knoble J, Rink C, Zacks R, Blau S, Brown C, Cantrell A, Namburi S, Polimera H, Rovito M, Edwin N, Herz K, Kennecke H, Monfared A, Sautter R, Cronin T, Elshoury A, Fleissner B, Griffiths E, Hernandez-Ilizaliturri F, Jain P, Kariapper A, Levine E, Moffitt M, O'Connor T, Smith L, Wicher C, Zsiros E, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Ferrario C, Lau S, Miller W, Rudski L, Santos Dutra M, Wilchesky M, Mahmood S, McNair C, Mico V, Dixon B, Kloecker G, Logan B, Mandapakala C, Cabebe E, Jha A, Khaki A, Nagpal S, Schapira L, Wu J, Whaley D, Lopes G, de Cardenas K, Russell K, Stith B, Taylor S, Klamerus J, Revankar S, Addison D, Chen J, Haynam M, Jhawar S, Karivedu V, Palmer J, Pillainayagam C, Stover D, Wall S, Williams N, Abbasi S, Annis S, Balmaceda N, Greenland S, Kasi A, Rock C, Luders M, Smits M, Weiss M, Chism D, Owenby S, Ang C, Doroshow D, Metzger M, Berenberg J, Uyehara C, Fazio A, Huber K, Lashley L, Sueyoshi M, Patel K, Riess J, Borno H, Small E, Zhang S, Andermann T, Jensen C, Rubinstein S, Wood W, Ahmad S, Brownfield L, Heilman H, Kharofa J, Latif T, Marcum M, Shaikh H, Sohal D, Abidi M, Geiger C, Markham M, Russ A, Saker H, Acoba J, Choi H, Rho Y, Feldman L, Gantt G, Hoskins K, Khan M, Liu L, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Zakharia Y, Friese C, Boldt A, Gonzalez C, Su C, Su C, Yoon J, Bijjula R, Mavromatis B, Seletyn M, Wood B, Zaman Q, Kaklamani V, Beeghly A, Brown A, Charles L, Cheng A, Crispens M, Croessmann S, Davis E, Ding T, Duda S, Enriquez K, French B, Gillaspie E, Hausrath D, Hennessy C, Lewis J, Li X, Prescott L, Reid S, Saif S, Slosky D, Solorzano C, Sun T, Vega-Luna K, Wang L, Aboulafia D, Carducci T, Goldsmith K, Van Loon S, Topaloglu U, Moore J, Rice R, Cabalona W, Cyr S, Barrow McCollough B, Peddi P, Rosen L, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncology 2023, 9: 128-134. PMID: 36326731, PMCID: PMC9634600, DOI: 10.1001/jamaoncol.2022.5357.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesCOVID-19COVID-19 TestingCytokine Release SyndromeFemaleHumansImmunosuppression TherapyImmunotherapyMaleMiddle AgedNeoplasmsRetrospective StudiesSARS-CoV-2ConceptsCOVID-19 severitySystemic anticancer therapyWorse COVID-19 severityCytokine stormBaseline immunosuppressionCohort studyAnticancer therapyCOVID-19Registry-based retrospective cohort studyIntensive care unit admissionCare unit admissionRetrospective cohort studyMulti-institutional registryLaboratory-confirmed infectionSevere clinical outcomesImmune system activationSARS-CoV-2Non-Hispanic whitesCOVID-19 diagnosisIO therapyPrevious cancerUnit admissionSecondary outcomesMedian agePrimary outcome
2022
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton S, Zannikou M, Ilut L, Fischietti M, Ji C, Oku C, Horvath C, Le Poole I, Bosenberg M, Bartom E, Kocherginsky M, Platanias L, Saleiro D. Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors. Molecular Cancer Research 2022, 21: 332-344. PMID: 36573964, PMCID: PMC10073316, DOI: 10.1158/1541-7786.mcr-22-0684.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmunosuppressive genesCheckpoint inhibitorsImmunostimulatory genesAnti-programmed cell death protein 1 therapyPharmacologic inhibitionIFNγ-induced expressionMelanoma cellsMajority of patientsTreatment of patientsTreatment of melanomaMelanoma tumor growthDrug target inhibitionICI therapyDurable responsesPatient survivalMetastatic melanomaPatient outcomesPoor survivalResponse rateTumor growthIFNγOverexpression of ULK1Context-dependent mannerMelanomaJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.Peer-Reviewed Original ResearchMeSH KeywordsDermatitis, AtopicHumansImmunosuppression TherapyJanus Kinase InhibitorsSkin NeoplasmsTreatment OutcomeVenous ThromboembolismConceptsIncidence of adverse eventsAdverse cardiac eventsNon-melanoma skin cancerSystemic therapyAdverse eventsAtopic dermatitisCardiac eventsJAK inhibitorsVenous thromboembolismControl patientsSkin cancerIncidence rateTreatment of atopic dermatitisSystemic immunosuppressive therapyRates of non-melanoma skin cancerTraditional systemic therapiesIncidence of malignancyLong-term clinical trial dataReference control populationAtopic dermatitis treatmentBaseline rateLow incidence rateClinical trial dataImmunosuppressive therapySystemic corticosteroidsCECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorFemaleHumansImmunosuppression TherapyMacrophagesMiceNeoplasm MetastasisNF-kappa BTranscription Factor RelATranscription FactorsConceptsBreast cancer metastasisReticuloendotheliosis viral oncogene homolog ACancer metastasisImmune suppressionM2 macrophagesWorse metastasis-free survivalMetastatic breast cancerMetastasis-free survivalV-rel avian reticuloendotheliosis viral oncogene homolog ACancer-related deathPrimary breast tumorsMultiple mouse modelsNF-κB signalingImmunocompetent settingNuclear factor-κB family membersMetastasis-promoting genesDistant metastasisMetastatic sitesPrimary tumorEffective therapyBreast cancerMetastasis treatmentMouse modelBreast tumorsMetastasisVaccination in pediatric solid organ transplant: A primer for the immunizing clinician
Chen JK, Cheng J, Liverman R, Serluco A, Corbo H, Yildirim I. Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician. Clinical Transplantation 2022, 36: e14577. PMID: 34997642, DOI: 10.1111/ctr.14577.Peer-Reviewed Original ResearchMeSH KeywordsChildHumansImmunosuppression TherapyOrgan TransplantationTransplant RecipientsVaccinationVaccinesConceptsVaccine-preventable illnessesPediatric solid organ transplant recipientsSolid organ transplant recipientsPediatric solid organ transplantCorrect immunization schedulesPrevention's Advisory CommitteeOrgan transplant recipientsSolid organ transplantsInfectious Diseases SocietyTime of transplantTransplant recipientsDiseases SocietyVaccine recommendationsIncomplete immunizationImmunization scheduleAntibody titersInadequate responseOrgan transplantsElevated riskPreventable illnessMultiple guidelinesVaccine managementRapid catchDisease controlAmerican Society
2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George L, Monahan P, Eyster M, Sullivan S, Ragni M, Croteau S, Rasko J, Recht M, Samelson-Jones B, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape K, Anguela X, High K. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. New England Journal Of Medicine 2021, 385: 1961-1973. PMID: 34788507, PMCID: PMC8672712, DOI: 10.1056/nejmoa2104205.Peer-Reviewed Original ResearchConceptsFactor VIII expressionAdeno-associatedHemophilia AAdverse eventsFactor VIIIGoal of gene therapyTreatment-related adverse eventsImmune responseAAV gene transferDiscontinuation of prophylaxisHighest-dose cohortLowest-dose cohortSafety observation periodAnnualized bleeding rateExpression of factor VIIICellular immune responsesFactor VIII activityFactor VIII assayGlucocorticoid-relatedVector doseDose cohortsVector administrationBleeding episodesVector genomesImmune suppressionImmunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function
Ramachandran R, Prabakaran R, Priya G, Nayak S, Kumar P, Kumar A, Kumar V, Agrawal N, Rathi M, Kohli H, Nada R. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function. Nephron 2021, 146: 138-145. PMID: 34818240, DOI: 10.1159/000518609.Peer-Reviewed Original ResearchMeSH KeywordsAdultGlomerulonephritis, MembranousHumansImmunosuppression TherapyImmunosuppressive AgentsKidneyProspective StudiesConceptsPMN patientsRenal dysfunctionAnti-PLA2RClinical remissionInduce remissionMembranous nephropathyFollow-upPrimary membranous nephropathyCompromised renal functionEnd-stage renal diseaseAdverse event profileProspective longitudinal observational studyPercentage of patientsCKD stage 3Immunosuppressive therapyImmunosuppressive treatmentLongitudinal observational studyRenal functionEvent profileCKD stageClinical outcomesUnit protocolRemissionNephrotic stateRenal diseaseRetinal and Choroidal Pathologies in Aged BALB/c Mice Following Systemic Neonatal Murine Cytomegalovirus Infection
Xu J, Liu X, Zhang X, Marshall B, Dong Z, Smith SB, Espinosa-Heidmann DG, Zhang M. Retinal and Choroidal Pathologies in Aged BALB/c Mice Following Systemic Neonatal Murine Cytomegalovirus Infection. American Journal Of Pathology 2021, 191: 1787-1804. PMID: 34197777, PMCID: PMC8485058, DOI: 10.1016/j.ajpath.2021.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgingAngiogenesis Inducing AgentsAnimalsAnimals, NewbornAntigens, ViralChoroidDNA, ViralGene Expression Regulation, ViralHerpesviridae InfectionsHost-Pathogen InteractionsImmunosuppression TherapyInflammationMice, Inbred BALB CMuromegalovirusPhagocytesRetinaRetinal Pigment EpitheliumTomography, Optical CoherenceVirus ActivationConceptsMurine cytomegalovirus infectionCytomegalovirus infectionChoroidal pathologiesVirus infectionSystemic murine cytomegalovirus infectionBALB/c miceAge-related macular degenerationAcute virus infectionRetinal pigment epithelium cellsDissemination of virusLatent virus infectionPigment epithelium cellsOcular latencyNeonatal infectionChoroidal atrophyHuman ocular diseasesOcular infectionsC miceSitu inflammationMacular degenerationOcular pathologyOcular diseasesPhotoreceptor degenerationAngiogenic factorsEpithelium cellsFace Transplantation in a Black Patient — Racial Considerations and Early Outcomes
Kauke M, Panayi AC, Tchiloemba B, Diehm YF, Haug V, Kollar B, Perry B, Singhal D, Sinha I, Riella LV, Annino DJ, Pomahac B. Face Transplantation in a Black Patient — Racial Considerations and Early Outcomes. New England Journal Of Medicine 2021, 384: 1075-1076. PMID: 33730460, PMCID: PMC8182672, DOI: 10.1056/nejmc2033961.Peer-Reviewed Original Research
2020
Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsRatsSwineTacrolimusTreatment OutcomeVascularized Composite AllotransplantationConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategiesClinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020, 72: 287-304. PMID: 32298473, PMCID: PMC7262242, DOI: 10.1002/hep.31281.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusComorbidityConsensusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug InteractionsGastroenterologyHumansImmunosuppression TherapyInternship and ResidencyLiver DiseasesLiver TransplantationOccupational HealthPandemicsPatient SafetyPneumonia, ViralPractice Guidelines as TopicSARS-CoV-2Tissue DonorsConceptsLiver transplant providersTransplant providersLiver diseaseHealthcare providersCOVID-19 pandemicExpert panel consensus statementLiver transplant recipientsCare of patientsCoronavirus disease 2019SARS-CoV-2 virusCOVID-19Transplant recipientsIll patientsLiver patientsClinical recommendationsConsensus statementDisease 2019PatientsPatient careDiseaseCareHepatologistsCOVID-19 pandemic impactBest practice advicePractice adviceComplete recovery of fulminant cytotoxic CD8 T‐cell‐mediated myocarditis after ECMELLA unloading and immunosuppression
Jurcova I, Rocek J, Bracamonte‐Baran W, Zelizko M, Netuka I, Maluskova J, Kautzner J, Cihakova D, Melenovsky V, Maly J. Complete recovery of fulminant cytotoxic CD8 T‐cell‐mediated myocarditis after ECMELLA unloading and immunosuppression. ESC Heart Failure 2020, 7: 1976-1981. PMID: 32485066, PMCID: PMC7373888, DOI: 10.1002/ehf2.12697.Peer-Reviewed Original ResearchMeSH KeywordsAdultCD8-Positive T-LymphocytesFemaleHeart-Assist DevicesHumansImmunosuppression TherapyMyocarditisTreatment OutcomeYoung AdultConceptsMechanical circulatory supportCirculatory supportT cell-mediated myocarditisTemporary mechanical circulatory supportThird-degree atrioventricular blockWeeks of supportSevere biventricular failureT-cell predominanceExtracorporeal membrane oxygenationPrevious cardiac historyBiventricular failureCardiogenic shockVentricular dysfunctionLymphocytic myocarditisCardiac historyEndomyocardial biopsyMembrane oxygenationAtrioventricular blockVentricular unloadingMacrophage expansionMyocarditisFlow cytometryComplete recoverySustained recoveryImmunosuppressionTreg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance
Sullivan J, Tomita Y, Jankowska-Gan E, Lema D, Arvedson M, Nair A, Bracamonte-Baran W, Zhou Y, Meyer K, Zhong W, Sawant D, Szymczak-Workman A, Zhang Q, Workman C, Hong S, Vignali D, Burlingham W. Treg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance. Cell Reports 2020, 30: 1039-1051.e5. PMID: 31995748, PMCID: PMC7042971, DOI: 10.1016/j.celrep.2019.12.081.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCoculture TechniquesExtracellular VesiclesFemaleForkhead Transcription FactorsGene Knockout TechniquesHeart TransplantationImmune ToleranceImmunosuppression TherapyInterleukin-12 Subunit p35InterleukinsMiceMice, Inbred C57BLMice, Inbred CBAMice, TransgenicMicroscopy, Electron, TransmissionMinor Histocompatibility AntigensReceptors, CytokineT-Lymphocytes, RegulatoryConceptsIL-35Treg cellsInfectious toleranceExtracellular vesiclesExpression of Ebi3T regulatory (Treg) cellsImmunosuppressive cytokinesInterleukin-35Peripheral toleranceRegulatory cellsEpstein-BarrBystander lymphocytesSecondary suppressionReporter miceB lymphocytesEBI3Protein 3Foxp3LymphocytesGene reporterNovel mechanismP35 proteinCellsEV productionTregs
2019
Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs
Shaheen M, Joo D, Ross J, Anderson B, Chen H, Huebert R, Li Y, Amiot B, Young A, Zlochiver V, Nelson E, Mounajjed T, Dietz A, Michalak G, Steiner B, Davidow D, Paradise C, van Wijnen A, Shah V, Liu M, Nyberg S. Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs. Nature Biomedical Engineering 2019, 4: 437-445. PMID: 31611679, PMCID: PMC7153989, DOI: 10.1038/s41551-019-0460-x.Peer-Reviewed Original ResearchConceptsHuman endothelial cellsEndothelial cellsSustained perfusionImmune responseContinuous perfusionNormal liver tissueHuman umbilical vein endothelial cellsUmbilical vein endothelial cellsImmunosuppression protocolsAnticoagulation therapyVein endothelial cellsImmunosuppressed pigsEndothelial markersLiver sinusoidsPerfusionLiver tissueHuman liverLiverBlood perfusionHeterotopic implantationMain predictorsLiver scaffoldsPigsPorcine liverDaysA novel mechanism of EAE resistance highlights the conflicting roles of progranulin-mediated immunosuppression and antigen processing
Hettinghouse A, Gao G, Liu C. A novel mechanism of EAE resistance highlights the conflicting roles of progranulin-mediated immunosuppression and antigen processing. Cellular & Molecular Immunology 2019, 18: 506-507. PMID: 31511641, PMCID: PMC8026965, DOI: 10.1038/s41423-019-0292-3.Peer-Reviewed Original ResearchAntigen PresentationImmune ToleranceImmunosuppression TherapyIntercellular Signaling Peptides and ProteinsProgranulins
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply